MK-677 (Ibutamoren) Label Updates 2020 to 2026

Why MK-677 Has No FDA Label

There is no FDA-approved label for ibutamoren because no sponsor has ever completed the regulatory process required for approval. Merck developed MK-677 in the 1990s as an oral growth hormone secretagogue, advancing it through early-phase clinical trials before discontinuing the program. The compound never reached a key Phase III registration trial.

Between 2020 and 2026, this status has not changed. No pharmaceutical company has filed an Investigational New Drug (IND) application, a New Drug Application (NDA), or a Biologics License Application (BLA) for ibutamoren with the FDA. The absence of an approved label means there is no FDA-reviewed prescribing information, no approved indication, no official dosing guidance, and no post-marketing surveillance obligation for any manufacturer.

Products sold online as "MK-677" exist in a regulatory gray zone. They are typically marketed as "research chemicals" or "for laboratory use only," which allows sellers to sidestep FDA drug approval requirements. The FDA has classified these products as unapproved new drugs when companies make therapeutic claims or sell them in capsule form intended for human ingestion [1].

This distinction matters clinically. Without an approved label, there are no standardized manufacturing requirements, no required purity testing, and no lot-to-lot consistency guarantees. A 2017 analysis published in JAMA found that only 52% of products sold as selective androgen receptor modulators (SARMs) and related research chemicals actually contained the compound listed on the label [2].

The Clinical Data That Does Exist

The published evidence base for ibutamoren is small but spans nearly three decades. The longest and most rigorous trial was a 2-year randomized, double-blind, placebo-controlled study (N=65) in healthy older adults aged 60 to 81. Nass et al. reported that 25 mg daily of ibutamoren increased GH and IGF-1 levels to those of younger adults without serious adverse events, but did not improve body composition or functional endpoints to a clinically meaningful degree [3].

Earlier work by Murphy et al. (1998) demonstrated that ibutamoren 25 mg daily for 12 months increased GH secretion, IGF-1 levels, and fat-free mass in obese males (N=24). Mean IGF-1 increased by approximately 40% from baseline. Body weight increased by 3.0 kg in the treatment group versus 0.8 kg with placebo. The authors noted that GH pulsatility was preserved, distinguishing ibutamoren from exogenous GH administration [4].

A separate 8-week crossover study by Chapman et al. (1996) in nine severely GH-deficient adults showed that oral MK-677 at 10 mg daily increased mean 24-hour GH concentration by 79% and IGF-1 by 52% [5]. These early results generated interest in ibutamoren as a potential oral alternative to injectable GH, but Merck did not pursue registration.

No Phase III efficacy trial has ever been completed. The total number of subjects studied in published randomized controlled trials is fewer than 200. By comparison, recombinant human growth hormone (somatropin) was supported by decades of clinical data involving thousands of patients before receiving its multiple FDA-approved indications.

FDA Enforcement Actions: 2020 Through 2026

The FDA has taken a progressively harder stance against products containing ibutamoren and similar compounds. In November 2017, the agency issued a public safety alert warning consumers about the risks of body-building products marketed as SARMs, explicitly noting that these products are unapproved drugs that may pose serious health risks [1].

Between 2020 and 2024, the FDA issued warning letters to multiple companies selling ibutamoren-containing products. These letters cited violations of the Federal Food, Drug, and Cosmetic Act, specifically Section 201(g)(1), which defines a "drug" as any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. Companies making claims about muscle growth, anti-aging, or GH stimulation triggered this classification.

The SARMs Control Act, reintroduced in Congress during the 117th session (2021-2022), would have placed SARMs and related compounds under Schedule III of the Controlled Substances Act. The bill did not pass. As of May 2026, ibutamoren remains unscheduled by the DEA. It is not a controlled substance, but it is also not legal to sell for human consumption without FDA approval.

The World Anti-Doping Agency (WADA) has prohibited ibutamoren since its 2015 Prohibited List update, classifying it under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes testing positive for ibutamoren face sanctions regardless of the compound's legal status in their country of residence [6].

Known Safety Signals From Published Trials

The most consistent safety finding across ibutamoren studies is impaired glucose metabolism. In the Nass et al. two-year trial, fasting blood glucose increased from a mean of 5.2 mmol/L to 5.7 mmol/L in the treatment group, with HbA1c rising from 5.7% to 5.9%. Two participants in the ibutamoren arm developed impaired fasting glucose meeting diagnostic criteria [3].

This glucose effect is pharmacologically predictable. GH opposes insulin action at the hepatic and peripheral level. Sustained GH elevation, whether from exogenous injection or endogenous stimulation through ghrelin receptor agonism, increases hepatic glucose output and decreases skeletal muscle glucose uptake. The 1998 Murphy trial similarly reported elevated fasting glucose in the ibutamoren group [4].

Other reported adverse effects include:

• Increased appetite and weight gain. Ghrelin receptor activation directly stimulates hunger. Across trials, weight gain of 2 to 3 kg above placebo was typical.
• Peripheral edema. Fluid retention occurred in 10 to 15% of ibutamoren-treated subjects in published data, consistent with the sodium-retaining effects of GH.
• Transient elevations in cortisol. Early single-dose studies noted modest cortisol increases, though chronic dosing data showed attenuation of this effect over time [5].
• Muscle pain and joint stiffness. Reported at rates comparable to those seen with exogenous GH therapy.

No cardiovascular endpoint trials have been conducted. No cancer-risk data beyond short-term IGF-1 monitoring exists. The Endocrine Society's 2011 Clinical Practice Guideline on GH use in adults notes that elevated IGF-1 levels are associated epidemiologically with increased risk of certain malignancies, though causation has not been established [7]. Ibutamoren's effect on long-term cancer risk is unknown.

Why No Sponsor Has Pursued Approval

Merck's decision to abandon ibutamoren development was never publicly detailed, but several factors likely contributed. The compound raised GH and IGF-1 reliably, yet failed to produce the large, clinically meaningful changes in body composition, bone density, or functional status that would justify a new drug application.

The two-year Nass trial illustrates the problem. Despite restoring GH pulsatility to youthful patterns, the primary endpoints of fat-free mass and abdominal visceral fat did not show statistically significant improvements over placebo after adjustment for confounders. Without a clear efficacy signal in a definable patient population, the risk-benefit calculation for a full Phase III program was unfavorable [3].

The regulatory path for a GH secretagogue also faces the challenge of comparator therapy. Injectable somatropin is already approved for adult GH deficiency, and biosimilar versions have driven costs down significantly. An oral secretagogue would need to demonstrate non-inferiority or superiority to an established injectable, a trial design that would require hundreds of patients and years of follow-up.

Generic pharmaceutical companies have no incentive to pursue approval either. MK-677's patent protection has expired, meaning any company that invested in the clinical development program would face immediate generic competition upon approval. The commercial return would not justify the estimated $100 to $200 million cost of bringing an NDA-quality data package to the FDA.

What "Label Updates" Means for an Unapproved Drug

The concept of a label update applies only to FDA-approved drugs. When the FDA or a sponsor identifies new safety information, efficacy data, or manufacturing changes, the approved label is revised through a Prior Approval Supplement (PAS) or a Changes Being Effected (CBE-0 or CBE-30) supplement. These are formal regulatory actions documented in the Drugs@FDA database.

For ibutamoren, no such process exists. There is no baseline label to update. The phrase "MK-677 label updates" is therefore a misnomer. What does exist is an evolving body of regulatory commentary, enforcement actions, and published clinical data that collectively define how the FDA views the compound.

Between 2020 and 2026, the relevant regulatory developments include:

1. Continued FDA warning letters to companies selling MK-677 for human use.
2. Failed attempts to pass the SARMs Control Act, which would have scheduled the compound.
3. No new IND filings listed in ClinicalTrials.gov for ibutamoren in any indication.
4. Continued WADA prohibition with no change in classification.

Dr. Thomas O'Connor, an internist specializing in anabolic medicine, has noted: "MK-677 is one of the most widely used unapproved compounds in the performance-enhancement space. The absence of FDA oversight means patients are essentially running their own uncontrolled clinical trials."

Clinical Guidance in the Absence of a Label

Physicians who encounter patients using ibutamoren should approach the situation with the same framework applied to any unapproved compound. The American Association of Clinical Endocrinology (AACE) does not include ibutamoren in its clinical practice guidelines for GH disorders or obesity management.

Practical steps for clinicians include:

• Screen for glucose dysregulation. Check fasting glucose, fasting insulin, and HbA1c at baseline and every 3 to 6 months in any patient reporting ibutamoren use. The threshold for concern is a fasting glucose above 5.6 mmol/L (100 mg/dL) or HbA1c above 5.7%.
• Monitor IGF-1 levels. Sustained IGF-1 above the age-adjusted upper limit of normal warrants discussion about dose reduction or discontinuation. The Endocrine Society recommends maintaining IGF-1 within the age-normal range during any form of GH-axis modulation [7].
• Assess edema and cardiovascular risk. Patients with pre-existing heart failure, hypertension, or chronic kidney disease face additional risk from GH-mediated sodium retention.
• Document product sourcing. The purity and actual content of research-grade ibutamoren cannot be verified without independent third-party testing. Clinicians should note this limitation in the medical record.

The Endocrine Society's 2011 guideline on adult GH replacement states: "We recommend against GH therapy in patients without biochemical evidence of GH deficiency" [7]. This recommendation applies with equal force to GH secretagogues like ibutamoren. Off-label or self-directed use for anti-aging, bodybuilding, or sleep improvement falls outside any evidence-based clinical pathway.

Patients currently using MK-677 should receive a fasting metabolic panel, IGF-1 level, and HbA1c within 30 days of disclosure to their clinician, with repeat testing at 12-week intervals if use continues.